SELLAS raises ~$20M in registered direct offering plus warrants priced at $1.535/share

SELLAS Life Sciences Group, Inc.

Gross proceeds of ~$20M from sale of 13,029,316 shares (or pre-funded warrants) at $1.535/share on Nasdaq.
Concurrent private placement of warrants to purchase up to 13,029,316 shares at $1.41, exercisable for 5.5 years.
Offering includes warrants exercisable immediately; closing expected March 19, 2024.
Net proceeds to fund R&D, working capital, and general corporate purposes.
A.G.P./Alliance Global Partners acting as sole placement agent with 7% cash fee.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

SELLAS Life Sciences Group, Inc. entered into Placement Agent Agreement with A.G.P./Alliance Global Partners (effective 2024-03-15).

Action: entry
Agreement: underwriting
Counterparty: A.G.P./Alliance Global Partners
Effective: 2024-03-15

Exact text from the filing

On March 15, 2024, the Company entered into a placement agency agreement (the “Placement Agent Agreement”) with A.G.P./Alliance Global Partners (“A.G.P.”) (the “Placement Agent”) pursuant to which the Company engaged A.G.P. as the exclusive placement agent in connection with the Offering.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

SELLAS Life Sciences Group, Inc. entered into Securities Purchase Agreement with institutional investors valued at approximately $20.0 million (effective 2024-03-15).

Action: entry
Agreement: equity purchase
Counterparty: institutional investors
Value: approximately $20.0 million
Effective: 2024-03-15

Exact text from the filing

On March 15, 2024, SELLAS Life Sciences Group, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with institutional investors (the “Investors”), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Investors (the “Registered Offering”), (i) an aggregate of 11,000,000 shares (the “Shares”) of common stock, par value $0.0001 per share, of the Company (“Common Stock”) and (ii) an aggregate of 2,029,316 pre-funded warrants exercisable for shares of Common Stock (the “Pre-Funded Warrants”) to the Investors.

View on SEC.gov

565 material agreements filed in the last 30 days. Browse all material agreements →

SELLAS Life Sciences Group, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-035028

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.